Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
A new target has been revealed for therapy for herpes simplex type 2. The target is RS1 mRNA whose activation is a key stage in regulating the expression of the early genes of herpes simplex virus type 2 (HSV-2). The targeted knockdown of the function of this gene by small interfering RNAs (siRNAs) has been found to result in the complete suppression of HSV-2 infection. The designed interfering RNAs are able to interact with both HSV-1 and HSV-2. The findings suggest that siRNAs have protective properties against the cytopathic effect of HSV-2 and cause no toxicity to infected Vero cells.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!